In “High-Risk” Infants with Sufficient Vitamin D Status at Birth, Infant Vitamin D Supplementation Had No Effect on Allergy Outcomes: A Randomized Controlled Trial
Nutrients
by Kristina Rueter 1,2,3,Anderson P. Jones 4,Aris Siafarikas 1,2,4OrcID,Ee-Mun Lim 5,6,Susan L. Prescott 1,2,3,7OrcID andDebra J. Palmer 1,4,*OrcID
400 IU was not enough to get Vitamin D levels above 30 ng
This organization (country?) mistakenly believes that have vitamin D levels above 20 ng was enough
This study also failed to consider the possibility that Vitamin D in blood is not acutally getting to the cells - due to genes
Download the PDF from Vitamin D Life
Lower vitamin D status at birth and during infancy has been associated with increased incidence of eczema and food allergies. The aim of this study was to investigate the effect of early infancy vitamin D supplementation on allergic disease outcomes in infants at “hereditary risk” of allergic disease, but who had sufficient vitamin D levels at birth. Here, we report the early childhood follow-up to 2.5 years of age of “high-risk” infants who participated in a double-blinded, randomized controlled trial. For inclusion in this trial, late gestation (36–40 weeks) maternal 25-hydroxyvitamin D levels needed to be ≥50 nmol/L. Infants were randomized to either oral vitamin D supplementation of 400 IU/day (n = 97) or a placebo (n = 98) for the first six months of life. Vitamin D levels and allergic disease outcomes were followed up. There were no statistically significant differences in incidence of any medically diagnosed allergic disease outcomes or allergen sensitization rates between the vitamin D-supplemented and placebo groups at either 1 year or at 2.5 years of age. In conclusion, for “allergy high-risk” infants who had sufficient vitamin D status at birth, early infancy oral vitamin D supplementation does not appear to reduce the development of early childhood allergic disease.